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Clinical and genetic heterogeneity in familial focal segmental in patients of diverse ethnic background, including indi-
glomerulosclerosis. viduals who are of Northern European, African, North
Background. Familial forms of focal segmental glomerulo- American, and Spanish descent. FSGS is a significantsclerosis (FFSGS) that exhibit autosomal dominant or recessive
cause of end-stage renal disease (ESRD), comprising uppatterns of inheritance have been described. The genetic basis
of these hereditary forms of FSGS is unknown. One recent study to 5% of adults and 20% of children with ESRD. Al-
of a kindred from Oklahoma with an autosomal dominant form though the idiopathic form of FSGS is the most common,
of FSGS linked this disease to a region of chromosome 19q. FSGS can also occur in association with reflux nephropa-In addition, polymorphisms in a gene in this region on chromo-
thy, human immunodeficiency virus (HIV) infection, andsome 19q13 have been linked to congenital nephrotic syndrome
of the Finnish type. We have ascertained and characterized a sickle cell disorder. Recently, autosomal dominant and re-
large family with autosomal dominant FFSGS (Duke 6530). cessive forms of familial FSGS have been described [1–8].
Methods. Families were compared for clinical and genetic The autosomal dominant form of FSGS is generally lessheterogeneity. To test for linkage of our family to this portion
severe, and patients present at a later age than with theof chromosome 19, genomic DNA was isolated from 102 family
autosomal recessive form. FSGS has also been associatedmembers, and polymerase chain reaction was performed using
eight microsatellite markers that spanned the area of interest with other congenital syndromes, including Laurence-
on chromosome 19. Data were evaluated using two-point link- Moon-Biedl syndrome [9], craniomandibular dermato-
age analysis, multipoint analysis, and an admixture test.
dysostosis [10], and Charcot-Marie-Tooth disease [11].Results. Linkage was excluded at a distance of 65 to 10 cm
The clinical hallmarks include proteinuria, nephroticfor all markers tested with two-point log10 of the odds of linkage
(LOD) scores and from an approximate 60 cm interval in this syndrome, and frequently the progressive loss of renal
area of chromosome 19q via multipoint analysis. function. Hypertension is also a common finding. The
Conclusions. FSGS has been called the “final common path-
diagnosis of FSGS is based on renal biopsy and requiresway” of glomerular injury, as it is a frequent pathological mani-
the presence of areas of glomerular sclerosis and tuftfestation with diverse etiologies. This diversity likely correlates
with the genetic heterogeneity that we have established. Thus, collapse that are both focal and segmental. Segmental
our data demonstrate that there are at least two genes responsi- hyalinosis, glomerular deposits that are positive for im-
ble for this disease, and there is genetic as well as clinical munoglobulin m and/or C3 by immunofluorescence mi-heterogeneity in autosomal dominant FSGS.
croscopy, and epithelial cell foot process effacement by
electron microscopy are often seen but are not required
to make the diagnosis.Focal segmental glomerulosclerosis (FSGS) is a patho-
The molecular basis of FSGS is not known. Previouslogical entity of unknown etiology. It has been reported
studies suggest that macrophages [12] or a circulating
factor in the plasma [13] may be involved in the develop-Key words: heredity, familial nephropathy, progressive renal disease,
glomerular sclerosis, tuft collapse. ment of the glomerular injury seen in FSGS. Other stud-
ies propose that FSGS is a disorder of mesangial extracel-Received for publication July 28, 1998
lular matrix metabolism [14]. Because FSGS occurs asand in revised form October 15, 1998
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familial forms of FSGS are relatively rare, identifying Individuals were categorized as “unknown” if they had
1 or 21 proteinuria or with 500 mg or less of proteinuriatheir genetic causes should contribute to understanding
on 24-hour collection and “unaffected” if they had nothe pathogenesis of the more common, sporadic forms
detectable proteinuria on qualitative urinalysis or wereof FSGS.
unrelated married-in spouses.A dominant form of familial renal disease character-
ized by proteinuria, progressive renal failure, and FSGS
Linkage analysison renal biopsy was described by Mathis et al and was
Duke family 6530 was analyzed as an autosomal domi-linked to a 7 Mb region of chromosome 19q spanned by
nant trait with variable penetrance. A frequency of 0.0001the microsatellite markers D19S223 and D19S213 [15].
was assumed for the FSGS disease allele. For those fam-Congenital nephrotic syndrome of the Finnish type has
ily members who were diagnosed as “affected,” a misclas-also been mapped to chromosome 19 [16]. Recently,
sification parameter of 0.005 was used. Those diagnosedvariants in a gene identified and named nephrin, which
as “probably affected” were assigned genotype pene-encodes a glomerular protein, have been shown to be the
trance values of 0.80 for the AA/Aa genotypes and 0.20defect in Finnish nephropathy, and this gene is located
for the aa genotype, where A represents the FSGS allele.within the region on chromosome 19 that is spanned
Individuals with the diagnosis of “unknown” were givenby D19S223 and D19S213 [17]. In this study, we have
a risk of 0.05 of carrying the FSGS allele. These frequen-investigated a large kindred with familial FSGS and
cies were assigned based on our previous observationstested for linkage of their renal disease to this area of
in this cohort (abstract; Am J Hum Genet 61:A116, 1997).chromosome 19.
Log10 of the odds of linkage (LOD) scores were calcu-
lated using the Vitesse Program Package [21]. Marker
METHODS allele frequencies were calculated using 100 unrelated
Ascertainment and evaluation white controls (http://www2.mc.duke.edu/depts/medicine/
medgen/). The marker allele/control frequencies did notClinical material on Duke family 6530 was initially
differ substantially from those calculated from the unre-identified by the Department of Nephrology, Christ-
lated spouses in the family (N 5 17). Additionally, achurch Hospital, Christchurch, New Zealand (Fig. 1).
low-penetrance “affecteds-only” analysis was performedEvaluation of this family included a complete family his-
to assure that results obtained were not due to asymp-tory and an assay of serum creatinine and urinalysis where
tomatic individuals who were nonpenetrant carriers ofappropriate. Asymptomatic individuals were examined
the FSGS gene. Map distances for the marker loci werefor proteinuria with qualitative urinalysis. Of the individ-
obtained from published data (http://www.gdb.org/) [15].uals who had undergone renal biopsy, renal pathology
Finally, to exclude the possibility that differences inslides were available for review in six cases, and the
diagnostic criteria between our study and that reportedpathology reports were reviewed on the remainder.
by Mathis et al could account for differences in the out-
come of the linkage analysis, we analyzed the data sepa-DNA isolation and genotyping
rately using the classification system as Mathis et al de-Genomic DNA was isolated from peripheral blood
scribed [15]. Heterogeneity was evaluated using thethrough the Center for Human Genetics, Duke Univer-
admixture test as implemented in the HOMOG com-sity Medical Center, using PureGenee. Genotyping was
puter program [22].carried out as described by Pericak-Vance et al, with
the microsatellite markers D19S714, D19S213, D19S425,
D19S208, D19S191, D19S220, D19S223, and D19S589 [18]. RESULTS
Touchdown polymerase chain reaction was performed
Family datausing a protocol as previously described in Hecker et al
[19], and markers were optimized with differing concen- Family 6530 (Fig. 1) is a 399 member kindred of British
trations of dimethyl sulfoxide as needed [20]. heritage dating back seven generations from the south
of New Zealand. Segregation of the disease in the family
Diagnostic criteria followed an autosomal dominant pattern of inheritance.
For linkage analysis, individuals were considered to Of the 14 renal biopsies that were available, 13 were
be “affected” if they had a renal biopsy demonstrating classified as FSGS, and one was classified as nonspecific
FSGS without evidence of other systemic diseases that glomerular changes without evidence of other types of
have been known to cause FSGS, if they were on dialysis, kidney disease. Fourteen deceased individuals had
or if they had undergone renal transplantation. Family ESRD. Fourteen living family members were on dialysis
members with 31 to 41 proteinuria by qualitative urinal- or had undergone renal transplantation, and three indi-
ysis, in the absence of other systemic diseases likely to viduals were found to have proteinuria greater than 31
by qualitative urinalysis. Blood samples for DNA werelead to proteinuria, were classified as “probably affected.”
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Fig. 1. Family 6530 pedigree (simplified for clarity).
obtained from a total of 102 individuals, including 13 19q13 in this family. Linkage was excluded (LOD ,
22.00) at a distance of 6 5 to 10 cm for all markers tested.affected, 2 probably affected, 17 unknown individuals (14
of which were below the mean age of presentation for As depicted in Figure 2, multipoint linkage analysis of
the markers D19S213, D19S191, and D19S223 conclu-FSGS) and 17 unaffected married-in spouses. Of the indi-
viduals evaluated with renal disease, the mean age at sively excludes a span of approximately 60 cm in this
region for both penetrance models.presentation to a physician was 33 (range 16 to 61 years),
with the majority being in their third and fourth decade. When individuals were reclassified based on the diag-
nostic criteria of Mathis et al, nine individuals movedThe mean amount of proteinuria on presentation to a
physician was 3.3 g per 24 hours (range 0.3 to 6.5), and from the “probably affected” and “unknown” categories
to the “affected” category [15]. Re-analysis of the datathe mean serum creatinine was 1.6 mg/dl (range 0.6 to
4.1). In the patients with ESRD, the average time be- using this classification scheme extended the region of
exclusion and thus did not change the outcome of thetween initial presentation and the development of ESRD
was 10 years (range 4 to 20 years). Medical problems analysis (data not shown). Furthermore, analysis of ho-
mogeneity using the full pedigree model combining thesuch as diabetes that might be an alternative cause of
proteinuria were not present among the individuals clas- two-point results from our study and the study of Mathis
et al confirmed evidence of locus heterogeneity [15]. Allsified as affected. Also, none of these individuals dis-
played any evidence of other congenital abnormalities. markers trended in support of heterogeneity. Marker
D19S191 showed significant evidence of heterogeneity
Linkage analysis under both the Duke and Mathis et al models with LOD
scores of 4.12 (Duke criteria) and 4.38 (Mathis et alThe results of the two-point LOD scores for full pedi-
gree and affecteds-only models is as shown in Table 1. criteria), respectively, which is equivalent to odds of
more than 10,000:1 in favor of heterogeneity.This analysis does not support linkage to chromosome
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Table 1. Full pedigree and affecteds only LOD scores
for all markers tested
Theta 0.00 0.05 0.10 0.15 0.20 0.30 0.40
Full Pedigree
D19S714 25.52 22.45 21.72 21.38 21.22 20.94 20.38
D19S213 2∞ 22.94 21.74 21.10 20.70 20.27 20.07
D19S425 2∞ 25.30 23.21 22.09 21.39 20.27 20.19
D19S208 29.87 23.01 21.83 21.18 20.76 20.60 20.07
D19S191 2∞ 24.79 23.17 22.24 21.59 20.29 20.18
D19S220 2∞ 25.08 22.72 21.47 20.72 20.03 0.08
D19S223 2∞ 26.26 23.44 21.95 21.05 20.16 0.09
D19S589 2∞ 24.85 22.99 21.94 21.26 20.49 20.14
Affecteds only
D19S714 21.50 20.16 20.09 20.11 20.36 20.64 20.34
D19S213 2∞ 22.20 21.22 20.74 20.47 20.19 20.08
D19S425 2∞ 25.15 23.26 22.21 21.53 20.71 20.26
D19S208 25.29 21.94 21.13 20.73 20.49 20.24 20.11
D19S191 2∞ 24.77 23.24 22.28 21.59 20.68 20.20
Fig. 2. Multipoint analysis of family 6530 using flanking markersD19S220 2∞ 23.34 21.63 20.79 20.32 0.07 0.12
(D19S213 and D19S223) and D19S191. The solid line signifies the “af-D19S223 2∞ 26.14 23.80 22.55 21.75 20.80 20.29
fecteds only” analysis for Duke 6530 families. The dashed line is theD19S589 2∞ 23.45 22.06 21.30 20.83 20.30 20.08
full pedigree analysis for the Duke 6530 families. The arrow on the
vertical axis denotes a LOD score of 22.00.
DISCUSSION
cells, and sclerosis of glomeruli, and both disorders typi-
We have reported a large kindred with familial FSGS. cally present with nephrotic syndrome. Finnish nephrop-
The pedigree analysis of kidney disease in this family is athy is different from familial FSGS in that it manifests
most consistent with an autosomal dominant inheritance at or shortly after birth, is most common in Finland, and
pattern. The patients with kidney disease typically pre- progresses to death in the first two years of life unless
sented initially to a physician in their third decade and kidney transplantation is performed. Our data indicate
had high-grade proteinuria with a progressive course that the familial FSGS in Duke family 6530 and Finnish
leading to ESRD in a relatively large percentage of af- nephropathy involve lesions at distinct genetic loci.
fected individuals. In this study, we have demonstrated We have excluded linkage of Duke 6530 to the 19q13
genetic heterogeneity within familial FSGS. Unlike the region. Our criteria for assigning the diagnosis of FSGS
analyses of another family with FSGS and patients with were very stringent, resulting in a conservative data set.
Finnish nephropathy, our studies conclusively exclude Despite this, we were able to exclude an approximately
linkage of renal disease in our family to chromosome 19q. 60 cm region with a full pedigree and affecteds-only
Indeed, inspection of the diagnostic data on our family model. Family members were not included in the analysis
suggests that the genetic heterogeneity observed may rep- if they had another possible etiology for their renal dis-
resent an underlying clinical heterogeneity between the ease. Additionally, analysis of homogeneity revealed sta-
two data sets as well (Table 2). Duke 6530 has a larger tistically significant heterogeneity for multiple markers.
proportion of individuals with high-grade proteinuria on There are many familial renal disorders that lead to
presentation, a more progressive course, and more indi- ESRD besides FSGS, including adult polycystic kidney
viduals who develop ESRD. The age of presentation disease, Alport’s nephropathy, and juvenile familial
to a physician was also generally earlier in our family. nephronophthisis [24–28]. Genes have been identified in
Interestingly, the main similarity between the two data each of these disorders. Because ESRD is a major public
sets was the pathology results. This divergence of clinical health problem, affecting greater than 200,000 patients
presentation supports the genetic linkage evidence pre- in the United States [29, 30], and idiopathic FSGS com-
sented here for the heterogeneity in FSGS. prises a significant proportion of these patients, it is es-
Finnish nephropathy is linked to chromosome 19 as sential to understand the molecular basis in hopes of
well, and a gene, which is mutated in this disorder (an developing rational treatments and preventions.
autosomal recessive congenital nephrotic syndrome), has There is much speculation as to the underlying basis
recently been cloned on 19q13.1 [16, 17, 23]. This is of of FSGS. It is unclear if FSGS is the result of a primary
interest because congenital nephrotic syndrome of the glomerular defect or a circulating factor [14]. The early
Finnish type has some similarities in pathology, as well recurrence of idiopathic FSGS after renal transplanta-
as clinical manifestations to FSGS. In both Finnish ne- tion makes the latter explanation appealing as a possibil-
phropathy and FSGS, there is evidence of tubular atro- ity. Others have queried environmental causes [31].
FSGS has been called the “final common pathway” ofphy, foot process effacement of glomerular epithelial
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Table 2. Clinical comparison of Duke and Mathis et al 5. Goodman DJ, Clarke B, Hope RN, Miach PJ, Dawborn JK:
Familial focal glomerulosclerosis: A genetic linkage to the HLAFSGS families
locus? Am J Nephrol 15:442–445, 1995
Duke Mathis et al [17] 6. Tejani A, Nicastri A, Phadke K, Sen D, Adamson O, Dunn I,
Calderon P: Familial focal segmental glomerulosclerosis. Int JNo. of individuals with
Pediatr Nephrol 4:231–234, 1983proteinuria . 1 g/24 hr 10a 10b
7. McCurdy FA, Butera PJ, Wilson R: The familial occurrence ofNo. of Individuals with
focal segmental glomerular sclerosis. Am J Kidney Dis 10:467–469,proteinuria , 1 g/24 hr 2 18
1987Male:Female 1:1 1:1
8. Naruse T, Hirokawa N, Maekawa T, Azato H, Ito K, Kaya H:Average age of presentation 3rd Decade 5th Decade
Familial nephrotic syndrome with focal glomerular sclerosis. AmNo. individuals with ESRD 28/46 12/47
J Med Sci 280:109–113, 1980
a Four individuals with qualitative urinalysis only are not included 9. Barakat AJ, Arianas P, Glick AD, Butler MG: Focal sclerosing
b Two individuals with diabetes are included glomerulonephritis in a child with Laurence-Moon-Biedl syn-
drome. Child Nephrol Urol 10:109–111, 1990
10. Pedagogos E, Flanagan G, Francis DM, Becker GJ, Danks
DM, Walker RG: A case of craniomandibular dermatodysostosis
associated with focal glomerulosclerosis. Pediatr Nephrol 9:354–
glomerular injury, as it is a common pathological mani- 356, 1995
11. Lemieux G, Neemeh JA: Charcot-Marie-Tooth disease and nephri-festation of diverse forms of renal injury (for example,
tis. Can Med Assoc J 97:1193–1198, 1967intravenous drug use, reflux nephropathy, medications,
12. Iwano M, Akai Y, Fujii Y, Dohi Y, Matsumura N, Dohi K:
and cancer) [32–38]. We speculate that this genetic heter- Intraglomerular expression of transforming growth factor-beta 1
(TGF-beta 1) mRNA in patients with glomerulonephritis: Quanti-ogeneity reflects the complex pathogenesis of FSGS.
tative analysis by competitive polymerase chain reaction. Clin ExpWith further research, novel genes may soon be identi-
Immunol 97:309–314, 1994
fied that are involved in the etiology of ESRD. With 13. Ebihara I, Suzuki S, Nakamura T, Fukui M, Yaguchi Y, Tomino
Y, Koide H: Extracellular matrix component mRNA expressionthe exclusion of the 19q region in Duke 6530, we are
in glomeruli in experimental focal glomerulosclerosis. J Am Socconducting a genome-wide screen to identify additional
Nephrol 3:1387–1397, 1993
regions and eventually, genes that will provide insight 14. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis
E, Lovell H, Warady B, Gunwar S, Chonko AM, Artero M,into the factors involved in the pathophysiology of FSGS.
Vincenti F: Circulating factor associated with increased glomerular
permeability to albumin in recurrent focal segmental glomerulo-Postscript
sclerosis. N Engl J Med 334:878–883, 1996
15. Mathis BJ, Kim SH, Calabrese MH, Seidman JG, Seidman CE,We are continuing to recruit families with FFSGS and
Pollack MR: A locus for inherited focal segmental glomeruloscle-are eager to hear from any physicians caring for patients
rosis maps to chromosome 19q13. Kidney Int 53:282–286, 1998
with this disorder and invite them to the International 16. Kestila M, Mannikko M, Holmberg C, Gyapay G, Weissenbach
J, Savolainen ER, Peltonen L, Tryggvason K: Congenital ne-Collaborative Group on Familial FSGS (http://www2.mc.
phrotic syndrome of the Finnish type maps to the long arm ofduke.edu/depts/medicine/medgen/index.html). Please con-
chromosome 19. Am J Hum Genet 54:757–764, 1994
tact Michelle P. Winn, M.D., Duke University Medical 17. Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready
Center, Box 3014, Durham, North Caroline, USA (Tel: P, Putaala H, Ruotsalainen V, Morita T, Nissinen M, Herva
R, Kashtan CE, Peltonen L, Holmberg C, Olsen A, Tryggvason919-681-5546, Fax 919-681-7894, E-mail: mwinn@chg.
K: Positionally cloned gene for a novel glomerular protein: Nephrinmc.duke.edu). is mutated in Congenital Nephrotic syndrome. Mol Cell 1:575–582,
1998
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